share_log

Citigroup Maintains Neutral on Biomarin Pharmaceutical, Lowers Price Target to $91

Benzinga ·  Apr 25 18:48

Citigroup analyst David Lebovitz maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and lowers the price target from $94 to $91.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment